{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:23:02Z","timestamp":1793294582890,"version":"4.5.0"},"reference-count":63,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Determine the effectiveness of purified native type I collagen matrix plus polyhexamethylene biguanide antimicrobial (PCMP) on cutaneous wounds.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A prospective cohort study of 307 patients (67 venous leg ulcers, 62 diabetic foot ulcers, 45 pressure ulcers, 54 post-surgical wounds and 79 other wounds) was conducted.\n            <jats:bold>Results:<\/jats:bold>\n            Cox wound closure for PCMP was 73% at week 32. The median time to wound closure was 17\u00a0weeks (Kaplan\u2013Meier). The incidence of PCMP-treated wounds showing &gt;60% reductions in areas, depths and volumes were 81, 71 and 85%, respectively.\n            <jats:bold>Conclusion:<\/jats:bold>\n            PCMP demonstrated clinically meaningful benefits to patients with various types of cutaneous wounds.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>Clinical Trial registration number:<\/jats:bold>\n            NCT03286452.\n          <\/jats:p>","DOI":"10.2217\/cer-2020-0058","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T12:26:36Z","timestamp":1591014396000},"page":"691-703","source":"Crossref","is-referenced-by-count":19,"title":["Type I collagen matrix plus polyhexamethylene biguanide antimicrobial for the treatment of cutaneous wounds"],"prefix":"10.57264","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2302-6468","authenticated-orcid":false,"given":"Michael A","family":"Bain","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Hoag Hospital, Newport Beach &amp; Irvine, CA\u00a092663, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J","family":"Koullias","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stony Brook School of Medicine, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Morse","sequence":"additional","affiliation":[{"name":"Yavapai Regional Medical Center, Prescott, AZ 86301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santina","family":"Wendling","sequence":"additional","affiliation":[{"name":"Organogenesis Inc., Canton, MA 02021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9040","authenticated-orcid":false,"given":"Michael L","family":"Sabolinski","sequence":"additional","affiliation":[{"name":"Sabolinski LLC, Franklin, MA 02038, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_7_3_2","first-page":"72","article-title":"Effect of a new purified collagen matrix with polyhexamethylene biguanide on recalcitrant wounds of various etiologies: a case series","volume":"30","author":"Lintzeris D","year":"2018","unstructured":"Lintzeris D, Vernon K, Percise H. Effect of a new purified collagen matrix with polyhexamethylene biguanide on recalcitrant wounds of various etiologies: a case series. Wounds 30(3), 72\u201378 (2018).","journal-title":"Wounds"},{"issue":"1","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"e2047","DOI":"10.1097\/GOX.0000000000002047","article-title":"Use of native type I collagen matrix plus polyhexamethylene biguanide for chronic wound treatment","volume":"7","author":"Oropallo AR","year":"2019","unstructured":"Oropallo AR. Use of native type I collagen matrix plus polyhexamethylene biguanide for chronic wound treatment. Plast. Reconstr. Surg. Glob. Open 7(1), e2047 (2019).","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"issue":"6","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"e2251","DOI":"10.1097\/GOX.0000000000002251","article-title":"Effect of native type I collagen with polyhexamethylene biguanide antimicrobial on wounds","volume":"7","author":"Bain MA","year":"2019","unstructured":"Bain MA, Thibodeaux KT, Speyrer MS, Carlson E, Koullias GJ. Effect of native type I collagen with polyhexamethylene biguanide antimicrobial on wounds. Plast. Reconstr. Surg. Glob. Open 7(6), e2251 (2019).","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"e_1_3_7_6_2","unstructured":"510(k) Premarket Notification. (2020). https:\/\/www.accessdata.fda.gov\/SCRIPTS\/cdrh\/cfdocs\/cfPMN\/pmn.cfm?ID=18685"},{"key":"e_1_3_7_7_2","unstructured":"AHRQ Technology Assessment Program. Skin substitutes for treating chronic wounds \u2013 draft technical brief. (2019). https:\/\/www.ahrq.gov\/sites\/default\/files\/wysiwyg\/research\/findings\/ta\/drafts-for-review\/skin-substitutes_draft.pdf"},{"key":"e_1_3_7_8_2","unstructured":"CMS Manual System. Pub 100-04 medicare claims processing. (2020). https:\/\/www.cms.gov\/Regulations-and-Guidance\/Guidance\/Transmittals\/2019Downloads\/R4204CP.pdf"},{"key":"e_1_3_7_9_2","unstructured":"510(K) SUMMARY K051647. (2020). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf5\/K051647.pdf"},{"issue":"1","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/wrr.12391","article-title":"WHS guidelines update: diabetic foot ulcer treatment guidelines","volume":"24","author":"Lavery LA","year":"2016","unstructured":"Lavery LA, Davis KE, Berriman SJ WHS guidelines update: diabetic foot ulcer treatment guidelines. Wound Repair Regen. 24(1), 112\u2013126 (2016).","journal-title":"Wound Repair Regen."},{"issue":"9","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/wound.2015.0635","article-title":"Challenges in the treatment of chronic wounds","volume":"4","author":"Frykberg RG","year":"2015","unstructured":"Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv. Wound Care 4(9), 560\u2013582 (2015).","journal-title":"Adv. Wound Care"},{"issue":"2","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jvs.2015.10.003","article-title":"The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine","volume":"63","author":"Hingorani A","year":"2016","unstructured":"Hingorani A, LaMuraglia GM, Henke P The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J. Vasc. Surg. 63(Suppl. 2), S3\u2013S21 (2016).","journal-title":"J. Vasc. Surg."},{"issue":"1","key":"e_1_3_7_13_2","first-page":"CD000265","article-title":"Compression for venous leg ulcers","author":"O'Meara S","year":"2009","unstructured":"O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst. Rev. (1), CD000265 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"e_1_3_7_14_2","first-page":"83","article-title":"Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies","volume":"18","author":"Kurz X","year":"1999","unstructured":"Kurz X, Kahn SR, Abenhaim L Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. Int. Angiol. 18(2), 83\u2013102 (1999).","journal-title":"Int. Angiol."},{"issue":"5","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.2337\/diacare.22.5.692","article-title":"Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis","volume":"22","author":"Margolis DJ","year":"1999","unstructured":"Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 22(5), 692\u2013695 (1999).","journal-title":"Diabetes Care"},{"issue":"6","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.2337\/diacare.26.6.1790","article-title":"The health care costs of diabetic peripheral neuropathy in the US","volume":"26","author":"Gordois A","year":"2003","unstructured":"Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26(6), 1790\u20131795 (2003).","journal-title":"Diabetes Care"},{"issue":"6","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/dc05-2425","article-title":"Risk factors for foot infections in individuals with diabetes","volume":"29","author":"Lavery LA","year":"2006","unstructured":"Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 29(6), 1288\u20131293 (2006).","journal-title":"Diabetes Care"},{"issue":"1","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13643-016-0329-y","article-title":"Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review","volume":"5","author":"J\u00e4rbrink K","year":"2016","unstructured":"J\u00e4rbrink K, Ni G, S\u00f6nnergren H Prevalence and incidence of chronic wounds and related complications: a protocol for a systematic review. Syst. Rev. 5(1), 152 (2016).","journal-title":"Syst. Rev."},{"issue":"3","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2337\/dc13-2176","article-title":"Burden of diabetic foot ulcers for medicare and private insurers","volume":"37","author":"Rice JB","year":"2014","unstructured":"Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care 37(3), 651\u2013658 (2014).","journal-title":"Diabetes Care"},{"issue":"5","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jvs.2014.05.009","article-title":"Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers","volume":"60","author":"Hicks CW","year":"2014","unstructured":"Hicks CW, Selvarajah S, Mathioudakis N Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. J. Vasc. Surg. 60(5), 1247\u20131254.e2 (2014).","journal-title":"J. Vasc. Surg."},{"issue":"5","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3111\/13696998.2014.903258","article-title":"Burden of venous leg ulcers in the United States","volume":"17","author":"Rice JB","year":"2014","unstructured":"Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. J. Med. Econ. 17(5), 347\u2013356 (2014).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.semvascsurg.2015.05.002","article-title":"Venous ulcers of the lower extremity: definition, epidemiology, and economic and social burdens","volume":"28","author":"Lal BK","year":"2015","unstructured":"Lal BK. Venous ulcers of the lower extremity: definition, epidemiology, and economic and social burdens. Semin. Vasc. Surg. 28(1), 3\u20135 (2015).","journal-title":"Semin. Vasc. Surg."},{"issue":"8","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/dmrr.2523","article-title":"Burden of diabetic foot disorders, guidelines for management and disparities in implementation in Europe: a systematic literature review","volume":"30","author":"van Acker K","year":"2014","unstructured":"van Acker K, L\u00e9ger P, Hartemann A, Chawla A, Siddiqui MK. Burden of diabetic foot disorders, guidelines for management and disparities in implementation in Europe: a systematic literature review. Diabetes Metab. Res. Rev. 30(8), 635\u2013645 (2014).","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"2","key":"e_1_3_7_24_2","first-page":"CD011255","article-title":"Skin grafting and tissue replacement for treating foot ulcers in people with diabetes","volume":"2","author":"Santema TB","year":"2016","unstructured":"Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst. Rev. 2(2), CD011255 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1524-475X.2009.00543.x","article-title":"Human skin wounds: a major and snowballing threat to public health and the economy","volume":"17","author":"Sen CK","year":"2009","unstructured":"Sen CK, Gordillo GM, Roy S Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 17(6), 763\u2013771 (2009).","journal-title":"Wound Repair Regen."},{"issue":"12","key":"e_1_3_7_26_2","first-page":"347","article-title":"A review of collagen and collagen-based wound dressings","volume":"20","author":"Brett D","year":"2008","unstructured":"Brett D. A review of collagen and collagen-based wound dressings. Wounds 20(12), 347\u2013356 (2008).","journal-title":"Wounds"},{"issue":"3","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1524-475X.2009.00489.x","article-title":"Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model","volume":"17","author":"Schierle CF","year":"2009","unstructured":"Schierle CF, De la Garza M, Mustoe TA, Galiano RD. Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Repair Regen. 17(3), 354\u2013359 (2009).","journal-title":"Wound Repair Regen."},{"issue":"5","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/wound.2014.0567","article-title":"Clinical biofilms: a challenging frontier in wound care","volume":"4","author":"Hurlow J","year":"2015","unstructured":"Hurlow J, Couch K, Laforet K, Bolton L, Metcalf D, Bowler P. Clinical biofilms: a challenging frontier in wound care. Adv. Wound Care 4(5), 295\u2013301 (2015).","journal-title":"Adv. Wound Care"},{"issue":"1","key":"e_1_3_7_29_2","first-page":"21","article-title":"Towards the identification of the common features of bacterial biofilm development","volume":"9","author":"Lasa I","year":"2006","unstructured":"Lasa I. Towards the identification of the common features of bacterial biofilm development. Int. Microbiol. 9(1), 21\u201328 (2006).","journal-title":"Int. Microbiol."},{"issue":"16","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2174\/1568026615666150414123800","article-title":"Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections","volume":"15","author":"Mihai M","year":"2015","unstructured":"Mihai M, Holban A, Giurcaneanu C Microbial biofilms: impact on the pathogenesis of periodontitis, cystic fibrosis, chronic wounds and medical device-related infections. Curr. Top. Med. Chem. 15(16), 1552\u20131576 (2015).","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12968\/jowc.2017.26.1.20","article-title":"The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data","volume":"26","author":"Malone M","year":"2017","unstructured":"Malone M, Bjarnsholt T, McBain AJ The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J. Wound Care 26(1), 20\u201325 (2017).","journal-title":"J. Wound Care"},{"issue":"2","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"e56846","DOI":"10.1371\/journal.pone.0056846","article-title":"Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection","volume":"8","author":"Pastar I","year":"2013","unstructured":"Pastar I, Nusbaum AG, Gil J Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection. PLoS ONE 8(2), e56846 (2013).","journal-title":"PLoS ONE"},{"issue":"2","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1078\/1438-4221-00196","article-title":"Mechanisms of antibiotic resistance in bacterial biofilms","volume":"292","author":"Stewart PS","year":"2002","unstructured":"Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292(2), 107\u2013113 (2002).","journal-title":"Int. J. Med. Microbiol."},{"issue":"1","key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1128\/AAC.47.1.317-323.2003","article-title":"Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin","volume":"47","author":"Walters MC","year":"2003","unstructured":"Walters MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob. Agents Chemother. 47(1), 317\u2013323 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000318264","article-title":"Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic","volume":"23","author":"H\u00fcbner N-O","year":"2010","unstructured":"H\u00fcbner N-O, Kramer A. Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic. Skin Pharmacol. Physiol. 23(1), 17\u201327 (2010).","journal-title":"Skin Pharmacol. Physiol."},{"issue":"1","key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000318237","article-title":"Polihexanide: a safe and highly effective biocide","volume":"23","author":"Kaehn K","year":"2010","unstructured":"Kaehn K. Polihexanide: a safe and highly effective biocide. Skin Pharmacol. Physiol. 23(1), 7\u201316 (2010).","journal-title":"Skin Pharmacol. Physiol."},{"issue":"6","key":"e_1_3_7_37_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/jac\/dkn125","article-title":"Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity","volume":"61","author":"Muller G","year":"2008","unstructured":"Muller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J. Antimicrob. Chemother. 61(6), 1281\u20131287 (2008).","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"e_1_3_7_38_2","first-page":"409","article-title":"Autolytic debridement and management of bacterial load with an occlusive hydroactive deressing impregnated with polyhexamethylene biguanide","volume":"88","author":"Mancini S","year":"2018","unstructured":"Mancini S, Cuomo R, Poggialini M, D'Aniello C, Botta G. Autolytic debridement and management of bacterial load with an occlusive hydroactive deressing impregnated with polyhexamethylene biguanide. Acta Biomed. 88(4), 409\u2013413 (2018).","journal-title":"Acta Biomed."},{"issue":"1","key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jval.2017.07.007","article-title":"An economic evaluation of the impact, cost, and medicare policy implications of chronic nonhealing wounds","volume":"21","author":"Nussbaum SR","year":"2018","unstructured":"Nussbaum SR, Carter MJ, Fife CE An economic evaluation of the impact, cost, and medicare policy implications of chronic nonhealing wounds. Value Health 21(1), 27\u201332 (2018).","journal-title":"Value Health"},{"issue":"2","key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/wound.2019.0946","article-title":"Human wounds and its burden: an updated compendium of estimates","volume":"8","author":"Sen CK","year":"2019","unstructured":"Sen CK. Human wounds and its burden: an updated compendium of estimates. Adv. Wound Care 8(2), 39\u201348 (2019).","journal-title":"Adv. Wound Care"},{"issue":"7","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/wound.2015.0668","article-title":"A predictive model for diabetic foot ulcer outcome: the wound healing index","volume":"5","author":"Fife CE","year":"2016","unstructured":"Fife CE, Horn SD, Smout RJ, Barrett RS, Thomson B. A predictive model for diabetic foot ulcer outcome: the wound healing index. Adv. Wound Care 5(7), 279\u2013287 (2016).","journal-title":"Adv. Wound Care"},{"issue":"5","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1067-2516(07)60001-5","article-title":"Diabetic foot disorders. A clinical practice guideline (2006 revision)","volume":"45","author":"Frykberg RG","year":"2006","unstructured":"Frykberg RG, Zgonis T, Armstrong DG Diabetic foot disorders. A clinical practice guideline (2006 revision). J. Foot Ankle Surg. 45(Suppl. 5), S1\u2013S66 (2006).","journal-title":"J. Foot Ankle Surg."},{"key":"e_1_3_7_43_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/dmrr.2707","article-title":"Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review","volume":"32","author":"Game FL","year":"2016","unstructured":"Game FL, Apelqvist J, Attinger C Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab. Res. Rev. 32, 154\u2013168 (2016).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"e_1_3_7_44_2","unstructured":"US FDA. Guidance for industry chronic cutaneous ulcer and burn wounds \u2013 developing products for treatment. (2006). https:\/\/www.fda.gov\/media\/71278\/download"},{"issue":"2","key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jtv.2019.01.001","article-title":"Prevention and treatment of pressure ulcers\/injuries: the protocol for the second update of the International Clinical Practice Guideline 2019","volume":"28","author":"Kottner J","year":"2019","unstructured":"Kottner J, Cuddigan J, Carville K Prevention and treatment of pressure ulcers\/injuries: the protocol for the second update of the International Clinical Practice Guideline 2019. J. Tissue Viability 28(2), 51\u201358 (2019).","journal-title":"J. Tissue Viability"},{"issue":"6","key":"e_1_3_7_46_2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.26.6.1879","article-title":"Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial","volume":"26","author":"Sheehan P","year":"2003","unstructured":"Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 26(6), 1879\u20131882 (2003).","journal-title":"Diabetes Care"},{"issue":"6","key":"e_1_3_7_47_2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2337\/diacare.26.6.1696","article-title":"Surrogate end points for the treatment of diabetic neuropathic foot ulcers","volume":"26","author":"Margolis DJ","year":"2003","unstructured":"Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 26(6), 1696\u20131700 (2003).","journal-title":"Diabetes Care"},{"issue":"3","key":"e_1_3_7_48_2","first-page":"44","article-title":"A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks","volume":"56","author":"Snyder RJ","year":"2010","unstructured":"Snyder RJ, Cardinal M, Dauphin\u00e9e DM, Stavosky J. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. Ostomy. Wound Manage. 56(3), 44\u201350 (2010).","journal-title":"Ostomy. Wound Manage."},{"key":"e_1_3_7_49_2","unstructured":"AARP Public Policy Institute. The medicare beneficiary population. (2020). https:\/\/assets.aarp.org\/rgcenter\/health\/fs149_medicare.pdf"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0031"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0001"},{"issue":"9","key":"e_1_3_7_52_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.25270\/wmp.2019.9.2634","article-title":"Evaluation of wound closure rates using a human fibroblast-derived dermal substitute versus a fetal bovine collagen dressing: a retrospective study","volume":"65","author":"Fitzgerald RH","year":"2019","unstructured":"Fitzgerald RH, Sabolinski ML, Skornicki M, Parsons NB. Evaluation of wound closure rates using a human fibroblast-derived dermal substitute versus a fetal bovine collagen dressing: a retrospective study. Wound Manag. Prev. 65(9), 26\u201334 (2019).","journal-title":"Wound Manag. Prev."},{"issue":"3","key":"e_1_3_7_53_2","first-page":"40","article-title":"The use of a novel antimicrobial and purified native collagen matrix to manage bioburden and support healing in challenging wounds: a clinical evaluation","volume":"7","author":"Brantley J","year":"2016","unstructured":"Brantley J, Park H, Sanchez PJ, Fitzgerald R. The use of a novel antimicrobial and purified native collagen matrix to manage bioburden and support healing in challenging wounds: a clinical evaluation. Wounds Int. 7(3), 40\u201345 (2016).","journal-title":"Wounds Int."},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0001"},{"issue":"5","key":"e_1_3_7_55_2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/wrr.12332","article-title":"Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting","volume":"23","author":"Kirsner RS","year":"2015","unstructured":"Kirsner RS, Sabolinski ML, Parsons NB, Skornicki M, Marston WA. Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen. 23(5), 737\u2013744 (2015).","journal-title":"Wound Repair Regen."},{"key":"e_1_3_7_56_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0031"},{"issue":"3","key":"e_1_3_7_57_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/wrr.12156","article-title":"Comparative effectiveness of a bilayered living cellular construct and a porcine collagen wound dressing in the treatment of venous leg ulcers","volume":"22","author":"Marston WA","year":"2014","unstructured":"Marston WA, Sabolinski ML, Parsons NB, Kirsner RS. Comparative effectiveness of a bilayered living cellular construct and a porcine collagen wound dressing in the treatment of venous leg ulcers. Wound Repair Regen. 22(3), 334\u2013340 (2014).","journal-title":"Wound Repair Regen."},{"issue":"4","key":"e_1_3_7_58_2","first-page":"36","article-title":"TIME heals all wounds","volume":"34","author":"Ayello EA","year":"2004","unstructured":"Ayello EA, Dowsett C, Schultz GS TIME heals all wounds. Nursing (Lond.) 34(4), 36\u201342 (2004).","journal-title":"Nursing (Lond.)"},{"issue":"6","key":"e_1_3_7_59_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1524-475X.2009.00543.x","article-title":"Human skin wounds: a major and snowballing threat to public health and the economy","volume":"17","author":"Sen CK","year":"2009","unstructured":"Sen CK, Gordillo GM, Roy S Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 17(6), 763\u2013771 (2009).","journal-title":"Wound Repair Regen."},{"issue":"10","key":"e_1_3_7_60_2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM199909023411006","article-title":"Cutaneous wound healing","volume":"341","author":"Singer AJ","year":"1999","unstructured":"Singer AJ, Clark RAF. Cutaneous wound healing. N. Engl. J. Med. 341(10), 738\u2013746 (1999).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_61_2","unstructured":"Global Skin and Wound Care Market Is Expected to Reach USD 25.98 Billion by 2025: Fior Markets. (2020). https:\/\/www.globenewswire.com\/news-release\/2020\/03\/04\/1995036\/0\/en\/Global-Skin-and-Wound-Care-Market-Is-Expected-to-Reach-USD-25-98-Billion-by-2025-Fior-Markets.html"},{"issue":"3","key":"e_1_3_7_62_2","doi-asserted-by":"crossref","first-page":"A73","DOI":"10.1016\/j.jval.2013.03.329","article-title":"Medical, drug, and work-loss costs of venous leg ulcers","volume":"16","author":"Rice JB","year":"2013","unstructured":"Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Medical, drug, and work-loss costs of venous leg ulcers. Value Health 16(3), A73 (2013).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_7_63_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/2229-3485.106383","article-title":"Placebo in clinical trials","volume":"4","author":"Gupta U","year":"2013","unstructured":"Gupta U, Verma M. Placebo in clinical trials. Perspect. Clin. Res. 4(1), 49 (2013).","journal-title":"Perspect. Clin. Res."},{"key":"e_1_3_7_64_2","unstructured":"World Medical Association. Declaration of Helsinki. Medical Research Involving Human Subjects. (2020). https:\/\/www.wma.net\/what-we-do\/medical-ethics\/declaration-of-helsinki\/"},{"key":"e_1_3_7_65_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1745-6215-15-167","article-title":"The challenge of recruiting patients into a placebo-controlled surgical trial","volume":"15","author":"Hare KB","year":"2014","unstructured":"Hare KB, Lohmander LS, Roos EM. The challenge of recruiting patients into a placebo-controlled surgical trial. Trials 15, 167 (2014).","journal-title":"Trials"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:17:45Z","timestamp":1679231865000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.2217\/cer-2020-0058"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0058","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}